Cer­tain GSK an­tibi­ot­ic brands are up for sale — re­port

Last month, GSK’s Em­ma Walm­s­ley laid the ground­work for the com­pa­ny’s planned bi­fur­ca­tion — con­sumer health­care and an R&D-fo­cused out­fit (in­clud­ing its his­tor­i­cal­ly sep­a­rate vac­cines unit) — by shed­ding off non-core as­sets like its der­ma­tol­ogy di­vi­sion. Now, it looks like some an­tibi­ot­ic prod­ucts are re­port­ed­ly al­so on the chop­ping block.

On Mon­day, Bloomberg in­di­cat­ed the British drug­mak­er is work­ing with fi­nan­cial ad­vis­ers to po­ten­tial­ly di­vest its $200 mil­lion-a-year cephalosporin an­tibi­ot­ic busi­ness, in­clud­ing the Zin­nat and For­tum brands, and the port­fo­lio could fetch sev­er­al hun­dred mil­lion US dol­lars, cit­ing peo­ple fa­mil­iar with the mat­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER